Chemed Zukünftiges Wachstum

NYSE:CHE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	2,763	N/A	N/A	N/A	1
12/31/2025	2,594	356	N/A	N/A	3
12/31/2024	2,430	313	N/A	N/A	3
3/31/2024	2,293	283	302	354	N/A
12/31/2023	2,264	273	273	330	N/A
9/30/2023	2,225	245	259	322	N/A
6/30/2023	2,187	226	280	345	N/A
3/31/2023	2,165	240	208	269	N/A
12/31/2022	2,135	250	253	310	N/A
9/30/2022	2,129	262	220	273	N/A
6/30/2022	2,141	277	284	334	N/A
3/31/2022	2,142	267	249	303	N/A
12/31/2021	2,139	269	250	309	N/A
9/30/2021	2,132	308	271	332	N/A
6/30/2021	2,121	303	283	344	N/A
3/31/2021	2,091	329	450	507	N/A
12/31/2020	2,080	319	430	489	N/A
9/30/2020	2,069	271	410	466	N/A
6/30/2020	2,021	263	413	470	N/A
3/31/2020	1,992	231	258	317	N/A
12/31/2019	1,939	220	248	301	N/A
9/30/2019	1,874	209	238	294	N/A
6/30/2019	1,837	201	218	275	N/A
3/31/2019	1,806	205	241	296	N/A
12/31/2018	1,783	206	234	287	N/A
9/30/2018	1,753	206	152	202	N/A
6/30/2018	1,727	190	123	183	N/A
3/31/2018	1,700	113	91	159	N/A
12/31/2017	1,667	98	N/A	162	N/A
9/30/2017	1,642	76	N/A	198	N/A
6/30/2017	1,617	67	N/A	162	N/A
3/31/2017	1,592	114	N/A	197	N/A
12/31/2016	1,577	109	N/A	135	N/A
9/30/2016	1,572	106	N/A	187	N/A
6/30/2016	1,566	108	N/A	175	N/A
3/31/2016	1,557	111	N/A	166	N/A
12/31/2015	1,543	110	N/A	172	N/A
9/30/2015	1,524	110	N/A	172	N/A
6/30/2015	1,496	106	N/A	135	N/A
3/31/2015	1,475	103	N/A	134	N/A
12/31/2014	1,456	99	N/A	110	N/A
9/30/2014	1,425	92	N/A	66	N/A
6/30/2014	1,408	85	N/A	111	N/A
3/31/2014	1,405	76	N/A	131	N/A
12/31/2013	1,413	77	N/A	151	N/A
9/30/2013	1,433	81	N/A	190	N/A
6/30/2013	1,447	84	N/A	162	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CHEDas prognostizierte Gewinnwachstum (13.1% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: CHEDie Erträge des Unternehmens (13.1% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: CHEDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: CHEDie Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: CHEDie Einnahmen des Unternehmens (6.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CHE in 3 Jahren voraussichtlich hoch sein wird

Chemed Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Chemed Corporation Reiterates Earnings Guidance for Full Year 2024

Price target increased by 10% to US$690

Chemed Corporation (NYSE:CHE) Full-Year Results: Here's What Analysts Are Forecasting For This Year

Chemed Corporation Provides Earnings Guidance for the Full-Year 2023

Chemed Corporation Provides Earnings Guidance for the Year 2022

Chemed Corporation Provides Earnings Guidance for the Year 2022

Recent updates

CEO, President & Director recently sold US$816k worth of stock

CEO, President & Director notifies of intention to sell stock

First quarter dividend of US$0.40 announced

Chemed Corporation Declares Quarterly Dividend, Payable on June 18, 2024

Chemed: Growth Does Not Justify The Current Stock Price

CEO, President & Director recently sold US$2.3m worth of stock

Here's Why Chemed Corporation's (NYSE:CHE) CEO Compensation Is The Least Of Shareholders' Concerns

Is Chemed Corporation (NYSE:CHE) Trading At A 50% Discount?

Chemed Corporation Reiterates Earnings Guidance for Full Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Chemed Corporation, Annual General Meeting, May 20, 2024

New major risk - Revenue and earnings growth

Executive Vice President exercised options and sold US$3.8m worth of stock

Executive Vice President recently sold US$1.3m worth of stock

Chemed Corporation to Report Q1, 2024 Results on Apr 24, 2024

Price target increased by 10% to US$690

Chemed Corporation (NYSE:CHE) Full-Year Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Now 22% overvalued after recent price rise

Third quarter dividend of US$0.40 announced

Chemed Corporation Declares Quarterly Dividend, Payable on March 15, 2024

Chemed Corporation to Report Q4, 2023 Results on Feb 27, 2024

The Price Is Right For Chemed Corporation (NYSE:CHE)

Chemed Corporation Appoints Michael D. Witzeman as Chief Financial Officer, Effective January 1, 2024

CEO, President & Director recently sold US$859k worth of stock

Chemed: Continues To Compound Shareholder Value At Double-Digit Returns

Executive Vice President recently sold US$580k worth of stock

Executive VP & CFO notifies of intention to sell stock

Chemed Corporation Announces the Retirement of David P. Williams as Chief Financial Officer Effective December 31, 2023

Chemed Corporation Announces the Retirement of David P. Williams as Chief Financial Officer Effective December 31, 2023

Executive VP & CFO exercised options to buy US$5.9m worth of stock.

CEO, President & Director recently sold US$1.7m worth of stock

Chemed Corporation Provides Earnings Guidance for the Full-Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

Chemed Corporation to Report Q3, 2023 Results on Oct 25, 2023

Chemed - Showcasing Why It's So Reliable

Chemed: Still Bullish On Economic Characteristics, But Risks Shouldn't Be Overlooked

CEO, President & Director recently sold US$2.1m worth of stock

Is Chemed Corporation (NYSE:CHE) Worth US$521 Based On Its Intrinsic Value?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Chemed Corporation to Report Q2, 2023 Results on Jul 26, 2023

Chemed (NYSE:CHE) Has A Rock Solid Balance Sheet

Executive Vice President notifies of intention to sell stock

Independent Director recently sold US$160k worth of stock

Independent Director notifies of intention to sell stock

CEO, President & Director recently sold US$2.2m worth of stock

CEO, President & Director exercised options and sold US$412k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

CEO, President & Director recently sold US$1.6m worth of stock

Executive VP & CFO recently sold US$2.1m worth of stock

CEO, President & Director recently sold US$1.0m worth of stock

CEO, President & Director exercised options to buy US$1.2m worth of stock.

Full year 2022 earnings: EPS misses analyst expectations

Chemed Q4 2022 Earnings Preview

Chemed Corporation Declares Quarterly Cash Dividend Payable on March 17, 2023

Chemed Corporation: Long-Term Tailwinds, But Remains A Hold

Chemed Corporation to Report Q4, 2022 Results on Feb 23, 2023

Is Chemed (NYSE:CHE) Using Too Much Debt?

Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean

VP & Director exercised options and sold US$226k worth of stock

CEO, President & Director recently sold US$1.0m worth of stock

Executive VP & CFO exercised options and sold US$2.3m worth of stock

Executive VP & CFO recently sold US$4.0m worth of stock

CEO, President & Director recently sold US$966k worth of stock

Chemed Corporation Declares Quarterly Cash Dividend on the Capital Stock, Payable on December 5, 2022

Chemed declares $0.38 dividend